Abstract
The AlkB family of Fe (II) and α-ketoglutarate-dependent dioxygenases works by removing alkyl substituents from alkylation-damaged nucleic acid bases through oxidative dealkylation, subsequently affecting tumor progression and patient prognosis. However, the specific roles of the AlkB family in Glioblastoma remain to be elucidated. By taking advantage of the abundant bioinformatics databases, such as GEPIA2, cBioPortal and TIMER, we performed a comprehensive analysis of the AlkB family in GBM, and managed to identify the significant prognostic hallmarks and therapeutic targets within this family. We found that the expression levels of ALKBH2 and ALKBH8 were significantly up-regulated in GBM compared with normal tissues. Meanwhile, the patients with high levels of ALKBH2 and ALKBH8 possessed significant poor overall survival (OS). In addition, the results suggested that the biological function of the AlkB family was closely related to DNA damage repair, cell metabolism, cell proliferation and tumor immune infiltration in GBM. Furthermore, the high expression of ALKBH8 in GBM was verified by immunohistochemistry. Taken together, this study could provide meaningful information about the aberrant AlkB family associated with GBM initiation and progression, and help clinicians precisely predict patient survival and select alternative therapeutic drugs.
Highlights
Glioblastoma (GBM) is the most common malignant primary tumor of the central nervous system, accounting for about 14.5% of all primary brain tumors and 48% of all malignant primary brain tumors [1]
The results revealed that the expression levels of ALKBH1/2/3/4/5/7/8/FTO were elevated, while the expression level of ALKBH6 was reduced compared with normal brain tissues (Figure 1A)
The results revealed that ALKBH2/4/7/8/FTO were highly or mediumly expressed, while ALKBH3/6 were lowly or not detected in GBM tissues (Figure 2B)
Summary
Glioblastoma (GBM) is the most common malignant primary tumor of the central nervous system, accounting for about 14.5% of all primary brain tumors and 48% of all malignant primary brain tumors [1]. It has the characteristics of easy recurrence, high malignancy and poor prognosis [2, 3]. In the United States, the average age-adjusted incidence of GBM is 3.21 per 100,000 population [1]. GBM patients have a poor prognosis with a 5-year survival rate of 7.2% and a median survival of 8 months [1]. Even after the most effective treatment, the average survival time of GBM patients is only 14.5-16.6 months [5].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
